These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 23717383)
61. Effectiveness and safety of abatacept for the treatment of patients with primary Sjögren's syndrome. Machado AC; Dos Santos LC; Fidelix T; Lekwitch I; Soares SB; Gasparini AF; Augusto JV; Junior NC; Trevisani VFM Clin Rheumatol; 2020 Jan; 39(1):243-248. PubMed ID: 31420813 [TBL] [Abstract][Full Text] [Related]
62. BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Quartuccio L; Salvin S; Fabris M; Maset M; Pontarini E; Isola M; De Vita S Rheumatology (Oxford); 2013 Feb; 52(2):276-81. PubMed ID: 22879463 [TBL] [Abstract][Full Text] [Related]
63. Articular and Peripheral Nervous System Involvement Are Linked to the Long-Term Outcome in Primary Sjögren's Syndrome: The Relevance of Single Organ Manifestations Rather Than a Composite Score as Predictors. Quartuccio L; Gandolfo S; Zabotti A; Zandonella Callegher S; Fabro C; De Vita S Front Immunol; 2019; 10():1527. PubMed ID: 31354708 [No Abstract] [Full Text] [Related]
64. EBV reactivation serological profile in primary Sjögren's syndrome: an underlying trigger of active articular involvement? Pasoto SG; Natalino RR; Chakkour HP; Viana Vdos S; Bueno C; Leon EP; Vendramini MB; Neto ML; Bonfa E Rheumatol Int; 2013 May; 33(5):1149-57. PubMed ID: 22955798 [TBL] [Abstract][Full Text] [Related]
66. Distinct clinical characteristics of anti-Ro/SSA-negative primary Sjögren's syndrome: data from a nationwide cohort for Sjögren's syndrome in Korea. Park Y; Lee J; Koh JH; Sung YK; Lee SS; Choe JY; Shim SC; Kim JM; Kwon SR; Kim HO; Chung SH; Park SH; Kwok SK Clin Exp Rheumatol; 2019; 37 Suppl 118(3):107-113. PubMed ID: 31376264 [TBL] [Abstract][Full Text] [Related]
67. Proteomic analysis of saliva: a unique tool to distinguish primary Sjögren's syndrome from secondary Sjögren's syndrome and other sicca syndromes. Baldini C; Giusti L; Ciregia F; Da Valle Y; Giacomelli C; Donadio E; Sernissi F; Bazzichi L; Giannaccini G; Bombardieri S; Lucacchini A Arthritis Res Ther; 2011; 13(6):R194. PubMed ID: 22117835 [TBL] [Abstract][Full Text] [Related]
68. The serological profiles of subgroup of primary Sjögren's syndrome correlation with the clinical features of parotid glands. Zheng L; Yu C; Yang C; Xie L; Shi H; Wang Z J Craniomaxillofac Surg; 2014 Oct; 42(7):1260-4. PubMed ID: 24767802 [TBL] [Abstract][Full Text] [Related]
69. Systemic activity and mortality in primary Sjögren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients. Brito-Zerón P; Kostov B; Solans R; Fraile G; Suárez-Cuervo C; Casanovas A; Rascón FJ; Qanneta R; Pérez-Alvarez R; Ripoll M; Akasbi M; Pinilla B; Bosch JA; Nava-Mateos J; Díaz-López B; Morera-Morales ML; Gheitasi H; Retamozo S; Ramos-Casals M; Ann Rheum Dis; 2016 Feb; 75(2):348-55. PubMed ID: 25433020 [TBL] [Abstract][Full Text] [Related]
70. [Salivary and serum beta 2-microglobulin in the diagnosis of primary Sjögren's syndrome]. Bianucci G; Campana G; Bongi SM; Palermo C; D'Agata A Minerva Med; 1992 Nov; 83(11):705-13. PubMed ID: 1461541 [TBL] [Abstract][Full Text] [Related]
71. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome. Seror R; Sordet C; Guillevin L; Hachulla E; Masson C; Ittah M; Candon S; Le Guern V; Aouba A; Sibilia J; Gottenberg JE; Mariette X Ann Rheum Dis; 2007 Mar; 66(3):351-7. PubMed ID: 16950808 [TBL] [Abstract][Full Text] [Related]
72. Role of Fms-like tyrosine kinase 3 ligand as a potential biologic marker of lymphoma in primary Sjögren's syndrome. Tobón GJ; Saraux A; Gottenberg JE; Quartuccio L; Fabris M; Seror R; Devauchelle-Pensec V; Morel J; Rist S; Mariette X; De Vita S; Youinou P; Pers JO Arthritis Rheum; 2013 Dec; 65(12):3218-27. PubMed ID: 23982978 [TBL] [Abstract][Full Text] [Related]
73. 18F-fluorodeoxyglucose positron emission tomography/computer tomography as an objective tool for assessing disease activity in Sjögren's syndrome. Cohen C; Mekinian A; Uzunhan Y; Fauchais AL; Dhote R; Pop G; Eder V; Nunes H; Brillet PY; Valeyre D; Fain O; Soussan M Autoimmun Rev; 2013 Sep; 12(11):1109-14. PubMed ID: 23810977 [TBL] [Abstract][Full Text] [Related]
74. Salivary gland ultrasonography as a predictor of clinical activity in Sjögren's syndrome. Fidelix T; Czapkowski A; Azjen S; Andriolo A; Trevisani VFM PLoS One; 2017; 12(8):e0182287. PubMed ID: 28783737 [TBL] [Abstract][Full Text] [Related]
75. Systemic involvement in primary Sjogren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry). Ramos-Casals M; Brito-Zerón P; Solans R; Camps MT; Casanovas A; Sopeña B; Díaz-López B; Rascón FJ; Qanneta R; Fraile G; Pérez-Alvarez R; Callejas JL; Ripoll M; Pinilla B; Akasbi M; Fonseca E; Canora J; Nadal ME; de la Red G; Fernández-Regal I; Jiménez-Heredia I; Bosch JA; Ayala MD; Morera-Morales L; Maure B; Mera A; Ramentol M; Retamozo S; Kostov B; ; Rheumatology (Oxford); 2014 Feb; 53(2):321-31. PubMed ID: 24162151 [TBL] [Abstract][Full Text] [Related]
76. Immunoglobulin KM and GM gene polymorphisms modify the clinical presentation of primary Sjögren's syndrome. Pertovaara M; Hurme M; Antonen J; Pasternack A; Pandey JP J Rheumatol; 2004 Nov; 31(11):2175-80. PubMed ID: 15517630 [TBL] [Abstract][Full Text] [Related]
77. Systemic manifestations of primary Sjögren's syndrome out of the ESSDAI classification: prevalence and clinical relevance in a large international, multi-ethnic cohort of patients. Retamozo S; Acar-Denizli N; Rasmussen A; Horváth IF; Baldini C; Priori R; Sandhya P; Hernandez-Molina G; Armagan B; Praprotnik S; Kvarnstrom M; Gerli R; Sebastian A; Solans R; Rischmueller M; Pasoto SG; Valim V; Nordmark G; Kruize A; Nakamura H; Hofauer B; Giacomelli R; Fernandes Moça Trevisani V; Devauchelle-Pensec V; Atzeni F; Gheita TA; Consani-Fernández S; Szántó A; Sivils K; Gattamelata A; Danda D; Kilic L; Bartoloni E; Bombardieri S; Sánchez-Guerrero J; Wahren-Herlenius M; Mariette X; Ramos-Casals M; Brito-Zerón P; Clin Exp Rheumatol; 2019; 37 Suppl 118(3):97-106. PubMed ID: 31464664 [TBL] [Abstract][Full Text] [Related]
78. The diagnosis value of beta 2-microglobulin and immunoglobulins in primary Sjögren's syndrome. Maddali Bongi S; Campana G; D'Agata A; Palermo C; Bianucci G Clin Rheumatol; 1995 Mar; 14(2):151-6. PubMed ID: 7789054 [TBL] [Abstract][Full Text] [Related]
79. Increased levels of circulating microparticles in primary Sjögren's syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activity. Sellam J; Proulle V; Jüngel A; Ittah M; Miceli Richard C; Gottenberg JE; Toti F; Benessiano J; Gay S; Freyssinet JM; Mariette X Arthritis Res Ther; 2009; 11(5):R156. PubMed ID: 19832990 [TBL] [Abstract][Full Text] [Related]
80. Overlap of ACA-positive systemic sclerosis and Sjögren's syndrome: a distinct clinical entity with mild organ involvement but at high risk of lymphoma. Baldini C; Mosca M; Della Rossa A; Pepe P; Notarstefano C; Ferro F; Luciano N; Talarico R; Tani C; Tavoni AG; Bombardieri S Clin Exp Rheumatol; 2013; 31(2):272-80. PubMed ID: 23343785 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]